| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | Director
2 companies
Edick Paul R serves as a See Remarks at XERS and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 6 buys and 0 sells. Those positions are worth an estimated $31.8M at current prices.
Historically, Edick Paul R's trades have earned a below-average insider score of 44/100 across 5 rated trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of +12.6%.
The biggest single holding is XERS (~$31.8M) as See Remarks. Net of sales, the recent Form 4 record there shows accumulation of 350,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 9, 2023 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Buy | 10,000 | $2.38 | $23,794.00 | +0.4% | -20.2% | -5.1% | |
| Dec 13, 2022 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Buy | 20,000 | $1.45 | $29,000.00 | +1.3% | -14.2% | +50.4% | |
| May 12, 2022 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Buy | 100,000 | $1.40 | $140,380.00 | +7.1% | +27.0% | +90.8% | |
| Nov 15, 2021 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Buy | 20,000 | $2.28 | $45,664.00 | +148.9% | -2.8% | -44.0% | |
| Nov 11, 2021 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Buy | 200,000 | $2.08 | $415,760.00 | +32.9% | +15.9% | -28.8% | |
| Aug 23, 2018 | ITRM Iterum Therapeutics Plc | Director | Buy | 500 | $10.44 | $5,218.70 | +2.0% | - | - |